Mavacamten

DB14921ApprovedInvestigationalSmall moleculeCardiac Myosin Inhibitor

Mavacamten is a myosin inhibitor used to treat obstructive hypertrophic cardiomyopathy. It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans.

Chemical structure of Mavacamten
Mechanism
Curator reviewed · 17 references
Primary indication
Mavacamten is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms by the FDA, Health Canada, and the EMA.Curator reviewed · 3 structured indications
Formula / weight
C15H19N3O2 · 273.336 g/mol (avg)
First approval
Canada, 2022 · United States, 2022 · European Union, 2023
Code names
BMS-986427 · MYK-461 · SAR-439152
Brand names
  • Camzyos

Resolves to

Structure
InChIKeyRLCLASQCAPXVLM-NSHDSACASA-NSMILESCC(C)N1C(=O)NC(N[C@@H](C)C2=CC=CC=C2)=CC1=O
Targets

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1,039Drug interactionsStructured to mechanism, not free text
Sign in
31Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
12ContraindicationsEach with its own population and attribute set
Sign in
43Marketed productsAcross 6 countries and 5 labellers
Sign in
1ATC codeIncluding every combination product, plus 24 drug categories
Sign in
24+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Mavacamten, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account